Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.
|Articles|January 1, 2003
Oncology NEWS International
- Oncology NEWS International Vol 12 No 1
- Volume 12
- Issue 1
Phase I Data on SAHA, a Histone Deacetylase Inhibitor
TARRYTOWN, New York-Aton Pharma, Inc and its collaborators presented phase I data on its oral histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) at the 14th Annual EORTC/NCI/AACR symposium, held in Frankfurt, Germany. The trial of patients with refractory solid tumors, lymphomas, and leukemias, being conducted with researchers at Memorial Sloan-Ket-tering Cancer Center, defined a safe daily oral dosing regimen.
Advertisement
TARRYTOWN, New YorkAton Pharma, Inc and its collaborators presented phase I data on its oral histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) at the 14th Annual EORTC/NCI/AACR symposium, held in Frankfurt, Germany. The trial of patients with refractory solid tumors, lymphomas, and leukemias, being conducted with researchers at Memorial Sloan-Ket-tering Cancer Center, defined a safe daily oral dosing regimen.
Evidence of antitumor activity was also observed. Of the 28 patients with solid tumors, one (larynx cancer) had a partial response, two (renal cell cancer and transitional cell cancer) had reduction in measurable disease, and one (papillary thyroid cancer) had stable disease for more than 2 months.
Articles in this issue
almost 24 years ago
Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launchedalmost 24 years ago
FDA Approves New Taxotere Indication as First-Line Therapy for NSCLCalmost 24 years ago
Most Cancer Pain Is Experienced at the Patient’s Homealmost 24 years ago
HHS Unites Its HIV Advisorsalmost 24 years ago
First NCI Health Disparity Grantsalmost 24 years ago
Pain Therapy Improves Quality of Life for Caregiversalmost 24 years ago
Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)almost 24 years ago
CD40L-Expressing Dendritic Cells Eliminate Breast Tumors in Micealmost 24 years ago
Safe Handling Tips for Use of Testosterone Gelalmost 24 years ago
Lumpectomy/Mastectomy Equivalent in Early Breast CancerAdvertisement
Related to this article
The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.
Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive non-muscle invasive bladder cancer.
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.
"We thought there might be a preventive effect towards the development from CHIP to CCUS to MDS, so it’s a sort of a continuum," said Kirsten Grønbæk, MD, PhD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
3
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
4
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
5